Johnson & Johnson Launches Lung Cancer Testing Initiative in UAE

Johnson & Johnson has launched an initiative in the United Arab Emirates to expand access to liquid biopsy testing for patients diagnosed with advanced non-small cell lung cancer. The programme is designed to cover the cost of testing for eligible patients whose insurance plans do not include this type of diagnostic service.
Testing will be conducted using technology from Guardant Health, which specialises in cancer diagnostics. The blood-based test can analyse up to 74 genes linked to cancer, with results available within seven days.
Non-small cell lung cancer accounts for approximately 80 to 85% of lung cancer cases globally, making it the most common form of the disease. Liquid biopsy testing helps identify genetic changes in cancer cells, providing data that can support more targeted treatment decisions.